Literature DB >> 25091669

Estimated impact and cost-effectiveness of rotavirus vaccination in India: effects of geographic and economic disparities.

Richard Rheingans1, John D Anderson2, Benjamin Anderson3, Poulomy Chakraborty4, Deborah Atherly5, Deepa Pindolia6.   

Abstract

India accounts for 23% of global rotavirus mortality in under-five children, with more than 100,000 deaths from rotavirus annually. Introduction of a vaccine in India is considered to be the most effective intervention for preventing rotavirus mortality. Recent research suggests that there is considerable variation in rotavirus mortality burden across regional, gender and socio-economic subpopulations within India. In addition, there is potential variability in who would likely receive rotavirus vaccine if introduced. We use available household data to estimate heterogeneity in rotavirus mortality risk, vaccination benefits, and cost-effectiveness across geographic and socio-economic groups within India. We account for heterogeneity by modeling estimated three-dose routine vaccinations as a proxy for a generalized rotavirus vaccine, and mortality for subpopulations of children aggregated by region and state, socio-economic status and sex, separately. Results are presented for six geographic regions and for Bihar, Uttar Pradesh, and Madhya Pradesh, three high mortality states accounting for 56% of national mortality estimates. Impact estimates accounting for disparities predict rotavirus vaccine introduction will prevent 35,000 deaths at an average cost of $118/DALY averted (7292 INR/DALY averted). Rotavirus vaccines are most cost-effective for the poor living in high mortality regions and states. Reductions in geographic and socio-economic disparities based on regional estimates could prevent an additional 9400 deaths annually, while reductions in socio-economic disparities in the three highest morality states alone could prevent an additional 10,600 deaths annually. Understanding the impact of heterogeneity can help improve strategies to maximize the benefits of rotavirus vaccination introduction, leading to fewer lives lost as a result of rotavirus disease.
Copyright © 2014. Published by Elsevier Ltd.

Entities:  

Keywords:  Cost-effectiveness; Disparities; Equity; India; Rotavirus; Vaccination

Mesh:

Substances:

Year:  2014        PMID: 25091669     DOI: 10.1016/j.vaccine.2014.05.073

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  10 in total

1.  Systematic Review and Meta-Analysis of Cost-effectiveness of Rotavirus Vaccine in Low-Income and Lower-Middle-Income Countries.

Authors:  Sabbir Haider; Usa Chaikledkaew; Montarat Thavorncharoensap; Sitaporn Youngkong; Md Ashadul Islam; Ammarin Thakkinstian
Journal:  Open Forum Infect Dis       Date:  2019-03-08       Impact factor: 3.835

2.  Health impact and cost-effectiveness of a domestically-produced rotavirus vaccine in India: A model based analysis.

Authors:  Johnie Rose; Laura Homa; Sharon B Meropol; Sara M Debanne; Roger Bielefeld; Claudia Hoyen; Mendel E Singer
Journal:  PLoS One       Date:  2017-11-03       Impact factor: 3.240

3.  Rotavirus vaccine will have an impact in Asia.

Authors:  Carl D Kirkwood; A Duncan Steele
Journal:  PLoS Med       Date:  2017-05-09       Impact factor: 11.069

Review 4.  Accounting for equity considerations in cost-effectiveness analysis: a systematic review of rotavirus vaccine in low- and middle-income countries.

Authors:  Marie-Anne Boujaoude; Andrew J Mirelman; Kim Dalziel; Natalie Carvalho
Journal:  Cost Eff Resour Alloc       Date:  2018-05-18

Review 5.  The impact of vaccination on gender equity: conceptual framework and human papillomavirus (HPV) vaccine case study.

Authors:  Allison Portnoy; Samantha Clark; Sachiko Ozawa; Mark Jit
Journal:  Int J Equity Health       Date:  2020-01-14

6.  Heterogeneity in potential impact and cost-effectiveness of ETEC and Shigella vaccination in four sub-Saharan African countries.

Authors:  John D Anderson; Farzana Muhib; Richard Rheingans; Thomas Wierzba
Journal:  Vaccine X       Date:  2019-09-20

7.  Enhancing viral vaccine production using engineered knockout vero cell lines - A second look.

Authors:  F Hoeksema; J Karpilow; A Luitjens; F Lagerwerf; M Havenga; M Groothuizen; G Gillissen; A A C Lemckert; B Jiang; R A Tripp; C Yallop
Journal:  Vaccine       Date:  2018-03-16       Impact factor: 3.641

8.  Optimal allocation of HIV resources among geographical regions.

Authors:  David J Kedziora; Robyn M Stuart; Jonathan Pearson; Alisher Latypov; Rhodri Dierst-Davies; Maksym Duda; Nata Avaliani; David P Wilson; Cliff C Kerr
Journal:  BMC Public Health       Date:  2019-11-12       Impact factor: 3.295

Review 9.  Introducing rotavirus vaccine in the Universal Immunization Programme in India: From evidence to policy to implementation.

Authors:  Akash Malik; Pradeep Haldar; Arindam Ray; Anita Shet; Bhrigu Kapuria; Sheenu Bhadana; Mathuram Santosham; Raj Shankar Ghosh; Robert Steinglass; Rakesh Kumar
Journal:  Vaccine       Date:  2019-08-30       Impact factor: 3.641

10.  Public finance of universal routine childhood immunization in India: district-level cost estimates.

Authors:  Emily Schueller; Arindam Nandi; Amit Summan; Susmita Chatterjee; Arindam Ray; Pradeep Haldar; Ramanan Laxminarayan
Journal:  Health Policy Plan       Date:  2022-02-08       Impact factor: 3.344

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.